The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI

Biomaterials

Volumn 32, Issue 22, 2011, Pages 5187-5194

  Yim, Hyeona ^a   Yang, Su Geun ^b,c   Jeon, Yong Sun ^c   Park, In Suh ^c   Kim, Mina ^b   Lee, Don Haeng ^b,c   Bae, You Han ^b,d   Na, Kun ^a  

^a The Catholic University of Korea   (South Korea)

^b Utah Inha DDS and Advanced Theapeutics Research Center   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Gadolinium; Hepatocyte specific contrast agent; Liver cancer; MRI; Pullulan; T1 contrast

Indexed keywords

HEPATOCYTE-SPECIFIC CONTRAST AGENT; LIVER CANCER; MRI; PULLULANS; T1 CONTRAST;

GENE TRANSFER; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING;

GADOLINIUM;

ASIALOGLYCOPROTEIN RECEPTOR; GADODIAMIDE; GADOLINIUM DIETHYLENETRIAMINE PENTAACETATE PULLULAN CONJUGATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; HEPATOBILIARY SYSTEM; IC 50; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ASIALOGLYCOPROTEIN RECEPTOR; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; GADOLINIUM DTPA; GLUCANS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MOLECULAR STRUCTURE; RATS;

RATTUS;

EID: 79956102075     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.069     Document Type: Article

References (36)

1. Koh D.M., Cook G.J., Husband J.E. New horizons in oncologic imaging. N Engl J Med 2003, 348:2487-2488.
2. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
3. Heiken J., Weyman P., Lee J., Balfe D., Picus D., Brunt E., et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989, 171:47-51.
4. Rofsky N., Weinreb J., Bernardino M., Young S., Lee J., Noz M. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993, 188:53-59.
5. Matsui O., Kadoya M., Kameyama T., Yoshikawa J., Takashima T., Nakanuma Y., et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991, 178:493-497.
6. Semelka R., Helmberger T. Contrast agents for MR imaging of the liver. Radiology 2001, 218:27-38.
7. Sitharaman B., Van Der Zande M., Ananta J.S., Shi X., Veltien A., Walboomers X.F., et al. Magnetic resonance imaging studies on gadonanotube-reinforced biodegradable polymer nanocomposites. J Biomed Mater Res A 2010, 93:1454-1462.
8. Pierre V.C., Botta M., Raymond K.N. Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength. J Am Chem Soc 2005, 127:504-505.
9. Grange C., Geninatti-Crich S., Esposito G., Alberti D., Tei L., Bussolati B., et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res 2010, 70:2180-2190.
10. Corot C., Robert P., Lancelot E., Prigent P., Ballet S., Guilbert I., et al. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med 2008, 60:1337-1346.
11. Shu C.Y., Ma X.Y., Zhang J.F., Corwin F.D., Sim J.H., Zhang E.Y., et al. Conjugation of a water-soluble gadolinium endohedral fulleride with an antibody as a magnetic resonance imaging contrast agent. Bioconjug Chem 2008, 19:651-655.
12. Chen W., Vucic E., Leupold E., Mulder W.J., Cormode D.P., Briley-Saebo K.C., et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008, 3:233-242.
13. Geninatti Crich S., Bussolati B., Tei L., Grange C., Esposito G., Lanzardo S., et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 2006, 66:9196-9201.
14. Swanson S.D., Kukowska-Latallo J.F., Patri A.K., Chen C., Ge S., Cao Z., et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomed 2008, 3:201-210.
15. Reimer P. Tumor-targeted MR contrast agents: hype or future hope?. Radiology 2004, 231:1-2.
16. Bellin M. MR contrast agents, the old and the new. Eur J Radiol 2006, 60:314-323.
17. Gandhi S.N., Brown M.A., Wong J.G., Aguirre D.A., Sirlin C.B. MR contrast agents for liver imaging: what, when, how. Radiographics 2006, 26:1621-1636.
18. Weinmann H.J., Ebert W., Misselwitz B., Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 2003, 46:33-44.
19. Rekha M., Sharma C. Pullulan as a promising biomaterial for biomedical applications: a perspective. Trends Biomater Artif Organ 2007, 20:116-121.
20. Trere D., Fiume L., De Giorgi L.B., Di Stefano G., Migaldi M., Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 1999, 81:404-408.
21. Yamaoka T., Tabata Y., Ikada Y. Body distribution profile of polysaccharides after intravenous administration. Drug Delivery 1993, 1:75-82.
22. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) Chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99:2293-2352.
23. Hosseinkhani H., Hosseinkhani M. Biodegradable polymer-metal complexes for gene and drug delivery. Curr Drug Saf 2009, 4:79-83.
24. Feng Y., Zong Y., Ke T., Jeong E.K., Parker D.L., Lu Z.R. Pharmacokinetics, biodistribution and contrast enhanced MR blood pool imaging of Gd-DTPA cystine copolymers and Gd-DTPA cystine diethyl ester copolymers in a rat model. Pharm Res 2006, 23:1736-1742.
25. Caravan P., Astashkin A.V., Raitsimring A.M. The gadolinium(III)-water hydrogen distance in MRI contrast agents. Inorg Chem 2003, 42:3972-3974.
26. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
27. Werner E.J., Datta A., Jocher C.J., Raymond K.N. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew Chem Int Ed Engl 2008, 47:8568-8580.
28. Marchal G., Zhang X., Ni Y., Van Hecke P., Yu J. AL.B. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 1993, 11:665-674.
29. Bonekamp S., Kamel I., Solga S., Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. J Hepatol 2009, 50:17-35.
30. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
31. Kindberg G.M., Uran S., Friisk G., Martinsen I., Skotland T. The fate of Gd and chelate following intravenous injection of gadodiamide in rats. Eur J Radiol 2010, 20:1636-1643.
32. Moonen C.T., van Zijl P.C., Frank J.A., Le Bihan D., Becker E.D. Functional magnetic resonance imaging in medicine and physiology. Science 1990, 250:53-61.
33. Lipinski M.J., Amirbekian V., Frias J.C., Aguinaldo J.G., Mani V., Briley-Saebo K.C., et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magnet Reson Med 2006, 56:601-610.
34. Erdogan S., Torchilin V.P. Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. Methods Mol Biol 2010, 605:321-334.
35. Chen Z., Yu D., Liu C., Yang X., Zhang N., Ma C., et al. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent. J Drug Target 2010, 1-9.
36. Tanimoto A., Kreft B.P., Baba Y., Zhao L., Finn J.P., Compton C.C., et al. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. J Magn Reson Imaging 1993, 3:786-793.